The likelihood approach for potential role of “GABRG2 (C588T, C315T) gene polymorphisms” on the poor response to carbamazepine therapy in Pakhtun population of Pakistan

Shakir Ullah\textsuperscript{a, b}, Niaz Ali\textsuperscript{c}, Sajjad Ahmad\textsuperscript{d}, Syed Wadood Ali Sha\textsuperscript{b}, Saad Ali\textsuperscript{d}, Feras Almarshad\textsuperscript{d}

Abstract

Background: Gamma-aminobutyric acid A receptor, gamma 2 gene (GABRG2) encode the GABAA receptor which is responsible for fast neuronal inhibition. Polymorphisms in GABGR2 gene affect the clinical response of anti-epileptic drugs (AEDs). Therefore, we carried out an updated study to find the association GABRG2 gene polymorphisms with carbamazepine (CBZ) non-responsive therapy in the Pakhtun population.

Methods: A clinical prospective cohort study was conducted in 79 CBZ treated patients upon consent after the approval of Khyber Medical University Advanced Study and Research Board. Blood sample were taken at optimal dose of CBZ at base line, third and sixth months of the treatment. Blood level of CBZ was measure through reverse phase high performance liquid chromatography (HPLC). Restriction fragment length polymorphisms techniques were used to genotype GABRG2 gene in these patients. CBZ responses were evaluated on three and six months of study by measuring the decrease in frequency of seizure per week.

Results: The average maximum dose of CBZ was 455 ± 133 mg/day at baseline, 479 ± 142 mg/day at third month and 495 ± 133 mg/day at sixth month of the treatment. CBZ level was found within therapeutic range (4-12 mg/L) without any significant (\( P > .5 \)) variations among the CC, CT and TT genotypes of GABRG2 (C588T and C315T) gene. But the poor clinical response during CBZ treatment was linked (\( P < .05 \)) with CT and TT genotypes of GABRG2 (C588T and C315T) gene in Pakhtun Population.

Conclusion: A poor response to CBZ was found in variant genotypes (CT and TT) of GABRG2 (C588T and C315T) gene in Pakhtun Population.

Abbreviations: AEDs = anti-epileptic drugs, CBZ = carbamazepine, GABRG2 = Gamma-aminobutyric acid A receptor, gamma 2 gene, KP = Khyber Pakhtunkhwa, SNPs = single nucleotide polymorphisms, VPA = valproic acid.

Keywords: Asia, carbamazepine, control response, GABRG2, Pakistan, poor response, valproic acid

1. Introduction

Epilepsy is a heterogenous nature brain disease, phenotypically exhibited by episodic seizures occurring within 24 hours.\textsuperscript{[1]} Carbamazepine (CBZ) is the anti-epileptic drug (AEDs) that is mostly used in generalized epilepsies in low developed countries.\textsuperscript{[2]} Non-responding therapy is an issue of neurologists.\textsuperscript{[3]} Pharmacoresistant epilepsy is a poor clinical response to CBZ treatment.\textsuperscript{[4]} Variable response to CBZ has been observed from different studies in various populations.\textsuperscript{[5]} Current published data demonstrates that problems in pharmacoresistance in epilepsy are the leading paradigm shifting to novel exciting therapies. Some patients show poor response to medical treatment and lead to pharmacoresistant epilepsy.\textsuperscript{[6]} Different studies suggest that genetic abnormalities are linked with the resistant epilepsy.\textsuperscript{[7]} This problem is highlighted by Argumosa and Herranz that poor controlled epilepsy was 2.7 times more expensive compared to controlled epilepsy.\textsuperscript{[8]} Variable response of CBZ may be due to alteration in gene encoding pharmacokinetic enzymes or encoding different AEDs binding receptors and ethnicity of individuals.\textsuperscript{[9]} However, Single nucleotide polymorphisms (SNPs) in gene is considered one of the main factors in genetic resistant epilepsy.\textsuperscript{[10]} It has been

Received: 13 August 2021 / Received in final form: 2 June 2022 / Accepted: 2 September 2022

http://dx.doi.org/10.1097/MD.0000000000030948
observed that these SNP is associated with resistant epilepsy due to abnormal conformational changes in ion channels and AEDs receptors.\[9\] Gamma-aminobutyric acid A receptor, gamma 2 gene (GABRG2) gene has attracted the attention of many scientists and has been explored in different population to find the link with different types of epilepsies. GABRG2 gene polymorphisms. Important mutations in GABRG2 genes are C315T and C588T which are responsible for different types of epilepsies.\[16\] However, few studies are available to find out the effect of GABRG2 gene polymorphisms on pharmacoresistance to AEDs.\[17–20\] The mechanisms underlying pharmacoresistance to AEDs is not still properly explored on scientific background.\[21\]

Therefore, this study is designed to find the link of GABRG2 (C315T, C315T) gene polymorphisms with pharmacoresistance to CBZ in Pakhtun population of Pakistan.

2. Methods

2.1. Participants recruitment

Epileptic patients (N = 79) properly diagnosed were enrolled upon a written consent from Outpatient Department of Neurology of Lady Reading Hospital, Peshawar. The study was approved by Advanced Study and Research Board and Ethical Board of Khyber Medical University, Peshawar via no: “DIR/KMU-EB/AC/0000047”. At baseline blood were taken for GABRG2 gene genotyping and at third and sixth month of the treatment for blood level of CBZ.

2.2. Protocol of the study

Study was a single center hospital based prospective study. Demographic and clinical features were recorded in a questionnaire at base line of the study. At the third and sixth months of treatment, the patients were followed up on, and the clinical outcome was assessed (Fig. 1). Clinical response was measured at third and sixth month of the treatment by measuring the reduction in frequency of seizure per week. Patients' reported outcomes (PRO) and clinician reported outcomes (CiRO) were used to determine clinical outcomes in epilepsy patients.\[22,23\]

Clinical results were documented on a standard established proforma in the context of local languages as a reduction in seizure frequency or duration.

2.3. Extraction of genomic DNA and GABRG2 gene genotyping

DNA was extracted from whole blood using kit method (NucleoSpin® Blood, Germany). Forward primer “5-CAAATGTGGTAATTAGTAACTGG-3” and reverse primer “5-TGATTCATTTTCTCAAACATGC-3” was used for the amplification of exon 3 of GABRG2 (C315T) gene. Restriction enzyme BasMI was used to digest the amplified products for genotyping. Furthermore, forward primer “5-AATCACCTTTATTTCTAATGTC-3” and reverse primer “5-CAGTGAAGGCAACCTTACTAAGA-3” used to amplify exons 5 of GABRG2 (C588T) gene using gradient PCR. The resultant product was restricted with digestive enzyme ApoI. 5% agarose was used to run the products of each exon and fragments were evaluated with 50Pb ladder.

2.4. Measurement of plasma level of CBZ

The blood level of CBZ was determined using reverse phase high performance liquid chromatography (LC-20AT Shimdzu Kyoto, Japan) at the third and sixth month of treatment. CBZ were extracted by adding 200 μL plasma to a solution of 50 μL of ammonium hydroxide (25%) (BDH Laboratory Supplies England) and 5mL of HPLC grade chloroform (Scharlab S.L. Spain). After appropriate mixing with a mechanical shaker for 20 minutes, the sample was centrifuged at 3000 rpm for 10 minutes using PLC-05 (Taiwan). The organic (chloroform) layer was evaporated after transferring to another tube at 50 °C in water bath. After drying the remaining were dissolved in the mobile phase (methanol: deionized water: glacial acetic acid 100%) at a ratio of 65:34:1 (v/v/v). Nylon membrane filter with Micropore 0.45 μm were used to filter the reconstituted extract.\[24\] About 20 μL reconstituted sample was injected into injection port of HPLC and flow rate of mobile phase through a C18 column (SEA 18, 5 µm 25 × 0.46 Mediterranean) was adjusted at 0.8 mL/min. Detection of CBZ was performed was observed on 220 nm.

2.5. Data analysis

GraphPad prism 6 was used to analyze the data. Results were shown in tables and figures. The data were presented in frequencies, mean ± SD. One way ANOVA followed by Tukey test was used to compare the blood level of CBZ at third and sixth month of the treatment among all genotypes of GABRG2 gene. Chi² test was used to find out the relationship of poor CBZ with variant genotypes of GABRG2 gene. Results were considered as statistically significant if (P > .05).

Figure 1. Timeline of study with CBZ dose and their therapeutic response. CBZ = carbamazepine.
3. Results

3.1. Clinical and demographic characteristics of epileptic patients

Mean age of the patients was 18.1 ± 8.2 year was at baseline, 17.84 ± 6.3 year at third month and 18.08 ± 7.5 year at sixth month of the treatment (Table 1). The frequency of female patients was high 41, 37, 34 (53%, 53.1%, 51.9%) female patients than male patients 37, 34, 28 (47%, 47.9%, 45.1%) at baseline, 3rd and 6th month of therapy (Table 1). Similarly, the frequency of generalized tonic clonic epilepsy was high in the enrolled patients (Table 1). The daily mean dose of CBZ was 455 ± 133 mg/day, 479 ± 142 mg/day and 495 ± 133 mg/day at baseline, third, and sixth month of the treatment. The observed clinical outcome was depicted in Figure 1.

3.2. Blood level of CBZ versus GABRG2 gene polymorphisms

The blood level of CBZ at third and sixth month of the treatment in different genotypes are presented in Figure 2. There was no significant (P < .05) difference in the blood level of CBZ in different genotypes of GABRG2 gene at third and sixth month of the treatment. Its mean that blood level was in therapeutic range and has no association with clinical outcome of CBZ (Fig. 2).

3.3. Measurement of the potential of GABRG2 (C588T, C315T) genotypes in CBZ treatment

Poor response to CBZ was observed in 46 patients at third month and 34 patients at sixth month of the treatment (Tables 2 and 3). It has found that variant genotypes of GABRG2 (588CT and 588TT) gene show an association ($\chi^2 = 9.9$, $P = .01$) with poor response to CBZ at third month of the treatment (Table 2). Similarly, again variant genotypes of GABRG2 (588CT and 588TT) gene showed an association ($\chi^2 = 11.2$, $P = .01$) with poor response to CBZ at sixth month of the treatment (Table 3).

In addition to, poor response to CBZ were more likely than those in responsive group to have 315CT and 315TT genotypes of GABRG2 gene ($\chi^2 = 9.4$, $P = .02$) at third month of CBZ treatment. More, poor response to CBZ were also more likely ($\chi^2 = 8.8$, $P = .03$) to happen in variant genotypes of GABRG2 (315CT, 315TT) gene at sixth month of CBZ treatment (Table 3).

4. Discussion

Our study delved the impact of GABRG2 (C588T and C315T) gene polymorphism on the clinical response of CBZ treatment in epileptic patients of Pakhtun population of Khyber Pakhtunkhwa, Pakistan. The clinical outcome was measure at third and sixth month of the treatment in the context of reduction of frequency of seizure per week. Our
was used.[27] It is recommended that further multicenter studies with CBZ treatment at third month (N = 71).

| Variables            | Poor seizure-controlled patients (n = 46) | Controlled patients (n = 25) |
|----------------------|-------------------------------------------|-----------------------------|
| Number (%)           | 46 (65)                                   | 25 (35)                     |
| Mean plasma level (mg/L) | 5.1 ± 2.0                                 | 5.6 ± 2.2                   |

GABRG2 (C588T) Gene. Heterozygous (588CT) genotypes were more likely frequent in CBZ resistant patients compared to CBZ responsive patients in Pakhtun population of KP (P = .03) comparing total patients of CBZ resistant versus total patients who are responsive to CBZ therapy. However, homozgyous mutant (588TT) genotypes were less likely frequent in CBZ therapy resistant patients as compared to CBZ responsive patients (P = .01) comparing resistant patients to CBZ therapy.

GABRG2 (C315T) Gene. Heterozygous (315CT) genotypes were more likely frequent in CBZ resistant patients compared to CBZ responsive patients in Pakhtun population of KP (P = .01) comparing total patients of CBZ resistant versus total patients who are responsive to CBZ therapy. However, homozgyous mutant (315TT) genotypes were less likely frequent in CBZ therapy resistant patients as compared to CBZ responsive patients (P = .07) comparing resistant patients to CBZ therapy.

CBZ = carbamazepine, GABRG2 = Gamma-aminobutyric acid A receptor, gamma 2 gene.

5. Conclusion

The variant genotypes (CT and TT) GABRG2 (C588T and C315T) gene is associated with poor response to CBZ in Pakhtun Population.

Acknowledgements

The authors also want to thank Professor Dr Adnan Khan and then Chief Executive of Govt. Lady Reading Hospital Peshawar for providing opportunity for research work.

Author contributions

Conceptualization: Shakir Ullah, Niaz Ali.
Data curation: Shakir Ullah.
Formal analysis: Shakir Ullah.
Investigation: Shakir Ullah, Saad Ali.
Methodology: Shakir Ullah.
Resources: Shakir Ullah, Sajjad Ahmad.
Writing – original draft: Shakir Ullah.
Writing – review &amp; editing: Shakir Ullah, Syed Wadood Ali Sha, Feras Almarshad.

References

[1] Cowan LD. The epidemiology of the epilepsies in children. Ment Retard Dev Disabil Res Rev. 2002;8:171–81.
[2] Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure. 1997;6:159–74.
[3] Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255–60.
[4] Cárdenas-Rodríguez N, Carmona-Aparicio L, Pérez-Lozano DL, et al. Genetic variations associated with pharmacoresistant epilepsy. Mol Genet Metab. 2020;21:1685–701.
[5] Arguás A, Herranz JJ. La repercusión económica de las enfermedades crónicas: El coste de la epilepsia infantil en el año 2000. Bol Pediatr. 2001;41:23–9.
[6] Hung C-C, Chang W-L, Ho J-L, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABC2C2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012;13:159–69.
[7] Prasad AN, Prasad C. Genetic influences on the risk of epilepsy. Pediatr Neurol. 2001. 117.
[8] Sigurdardottir L, Poduri A. Inherited epilepsies. In David R. Lynch: Neurogenetics: Scientific and Clinical Advances. New York: Taylor and Francis. 2006. 427–67.
[9] Ssodiya SM. Etiology and pathology of epilepsies: overview. In: Atlas of Epilepsies. Sanjay M.Ssodiya: Springer. 2010. 65–8.
[10] Macdonald RL, Olsen RW. GABAA receptor channels. Annu Rev Neurosci.. 1994;17:569–602.
[11] Shivers BD, Killisch I, Sprengel R, et al. Two novel GABAA receptor subunits exist in distinct neuronal subpopulations. Neuron. 1989;3:327–37.
[12] Arslan A. Specifying molecular determinants of the subcellular targeting of synaptic and extrasynaptic GABA A receptors. 2006.
[13] Mulligan MK, Wang X, Adler AL, et al. Complex control of GABA (A) receptor subunit mRNA expression: variation, covariation, and genetic regulation. PLoS One. 2012;7:e34586.
[14] Chou I-C, Lee C-C, Tsai C-H, et al. Association of GABRG2 polymorphisms with idiopathic generalized epilepsy. Pediatr Neurol. 2007;36:40–4.
[15] Moshei SL. Mechanisms of action of anticonvulsant agents. Neurology. 1999;55(5 Suppl 1):S32–40; discussion S54–8.
[16] Bethmann K, Fritschy J-M, Brandt C, et al. Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis. 2008;31:169–87.
[17] Kumar R, Lakhani R, Kalita J, et al. Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population. Seizure. 2010;19:237–41.
[18] Balan S, Sathyaraj S, Radha SK, et al. GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures. Pharmacogenet Genomics. 2013;23:605–10.
[19] El Ella SSA, Tawfik MA, El Fotoh WMMA, Soliman OA. The genetic variant “C588T” of GABARG2 is linked to childhood idiopathic generalized epilepsy and resistance to antiepileptic drugs. Seizure. 2018;60:39–43.
[20] Butilä AT, Zazgyva A, Sin AI, et al. GABRG2 C588T gene polymorphisms might be a predictive genetic marker of febrile seizures and generalized recurrent seizures: a case-control study in a Romanian pediatric population. Arch Med Sci. 2018;14:157.
[21] Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol. 2006;10:57–65.
[22] Velentgas P, Dreyer NA, Wu AW. Outcome definition and measurement. In: Velentgas P, Dreyer NA, Nourjah P, et al., editors. Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide. Rockville (MD): Agency for Healthcare Research and Quality (US). 2013.
[23] Willke RJ. Measuring the value of treatment to patients: patient-reported outcomes in drug development. Am Health Drug Benefits. 2008;1:34–40.
[24] Ezzeldin E, Shahat AA, Basudan OA. Development and validation of an HPLC method for the determination of carbamazepine in human plasma. Life Sci J. 2013;10.
[25] Ramachandran V, Shorvon SD. Clues to the genetic influences of drug responsiveness in epilepsy. Epilepsia. 2003;44:33–7.
[26] Benarroch EE. GABAA receptor heterogeneity, function, and implications for epilepsy. Neurology. 2007;68:612–4.
[27] Dequeker E, Ramsden S, Grody WW, et al. Quality control in molecular genetic testing. Nat Rev Genet. 2001;2:717–23.